Annals of internal medicine|2025|Lesser L
GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].
Randomized Controlled Trial
PMID: 41183340
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].
AIMS: One of the recent growing complications of neoplastic chemotherapy that is considered a challenge in their therapeutic protocol is testicular dysfunction. The pathogenesis of testicular injury is multifactorial, involving various pathogenic mec…
BACKGROUND AND AIMS: In the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants with type 2 diabetes and chronic kidney disease (CKD). These prespecified analyses assessed the effects of sema…
The current known data on the involvement of the peptidergic systems in breast cancer progression is overwhelmingly vast. Peptidergic systems are useful tools for imaging, diagnosis, prognosis and treatment of breast cancer. These systems play a cruc…
IntroductionDiabetes related foot ulcers (DFUs) are common complications of type 2 diabetes mellitus (T2DM), affecting 15-25% of individuals living with diabetes and significantly contributing to healthcare costs ($9-13 billion annually in the U.S.).…
Obesity is a global health concern with new medication treatment options. So far, research on how programs with newer anti-obesity medication (AOM) for the moderate- to high-risk population can mitigate the prevalence of obesity and reduce the econom…
OBJECTIVE: This secondary analysis of the Semaglutide Treatment Effect in People with obesity (STEP) TEENS (NCT04102189) study investigated the effect of semaglutide 2.4 mg versus placebo on insulin sensitivity and cardiometabolic risk factors. RESEA…
AIMS: Trials of the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs) found mean weight losses of 15%-21%, yet realworld dose titration and persistence remain suboptimal, limiting effectiveness. This study aims to determine real-world titration, pe…
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is currently the most common type of chronic liver disease. Semaglutide is a glucose-lowering drug administered for the treatment of type 2 diabetes mellitus (T2DM) and is clinically effective i…
Injectable antiobesity medications (AOMs), including liraglutide, semaglutide, and tirzepatide, have demonstrated significant efficacy in promoting weight loss and improving glycemic control. However, the extent to which diet and food intake and rela…
Disease-modifying treatments for major neurocognitive disorders, including Alzheimer's disease, Parkinson's disease and other cognitive deficits, are among the main unmet needs in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs),…
INTRODUCTION: Glucagon-Like Peptide-1 Receptor (GLP1R) agonists have become widespread anti-obesity/diabetes pharmaceuticals in the United States. AIM: This article aimed to provide our current knowledge on the plausible mechanisms linked to the role…
IMPORTANCE: Glucagon-like peptide 1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, provide cardiometabolic benefits to patients with type 2 diabetes and obesity, but their potential benefits in mitigating neurodegenerative and cer…
BACKGROUND: Diabetic kidney disease (DKD) is a major microvascular complication of diabetes, often progressing silently and leading to end-stage kidney disease (ESKD) and cardiovascular morbidity. Early identification and risk-adapted intervention ar…
BACKGROUND: Type 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction, which significantly impacts the quality of life. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown potential neuroprotective effects. This…
It was the aim of this study to evaluate the potential of reverse micelles (RM) and hydrophobic ion pairs (HIP) for incorporation of semaglutide into self-emulsifying oral drug delivery systems. Reverse micelles loaded with semaglutide were formed wi…
BACKGROUND: Semaglutide has shown potential liver benefits in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). However, no direct comparisons have been made between semaglutide and other antidiabetic medications, incl…
PURPOSE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are important therapeutic options for type 2 diabetes and obesity; however, concerns about ophthalmic safety persist. This study examined associations between GLP-1 RAs and ocular adverse…